Spectrum Equity, the growth equity firm behind Definitive Healthcare, PWNHealth, and more, is pleased to announce Jeff Haywood and Steve LeSieur have been named to GrowthCap’s Top 25 Healthcare Investors of 2023 list.

GrowthCap selected nominations from over 350 pre-qualified firms and placed considerable weight on feedback from portfolio company CEOs, colleagues, and peers in the industry. According to the publication, this year’s awardees have highly specialized knowledge, are keenly aware of sub-sector areas to focus on, work effectively with management teams, and operate strategically to consistently produce successful outcomes.

“The overarching goal was to determine those investors who have demonstrated the attributes to sustain a high level of investment performance – past, present, and future,” said the publication.

Jeff and Steve lead Spectrum’s healthcare practice, which focuses on high growth internet-enabled software and information services companies serving all parts of the healthcare market. With broad experience and investments spanning some of the most dynamic and critical parts of the healthcare market today, they have unique domain expertise and perspective across many market cycles and end markets, including consumer directed healthcare; providers; clinical diagnostics & laboratory; health plans & payer organizations; prescription drug spend & pharmacy access solutions; pharma & life sciences; and telehealth.

Jeff and Steve play key roles in establishing long-standing partnerships with CEOs and management teams, and they work alongside their portfolio companies to assist them with optimizing go-to-market motions, product roadmap prioritization, pricing & packaging considerations, and market expansion. They have also helped guide management teams through exits to strategic acquirers, financial sponsors and the public markets.

Jeff Haywood, Managing Director, Spectrum Equity

Jeff joined Spectrum in 2007 and currently serves on the board of Definitive Healthcare (NASDAQ: DH), RxVantage and Membersy. He also led Spectrum’s investment in PWNHealth and subsequent sale to Everlywell, where he continues as a board observer. Jeff was previously involved with GoodRx (NASDAQ: GDRX), Payer Compass (acquired by Zelis Healthcare), Net Health (acquired by The Carlyle Group), Verisys (acquired by Aperture Health). Passport Health Communications (acquired by Experian), and MedHOK (acquired by Hearst Health).

“Our approach to healthcare is straightforward. We partner with companies that leverage software and data in unique ways to achieve one or several key objectives: improving access to care; driving better outcomes; and lowering the cost of care across our healthcare system.”
– Jeff Haywood

Steve LeSieur, Managing Director, Spectrum Equity

Steve joined Spectrum in 2005 and currently serves on the board of GoodRx (NASDAQ: GDRX). He was previously involved with Payer Compass (acquired by Zelis Healthcare), Definitive Healthcare (NASDAQ:DH), MedHOK (acquired by Hearst Health), HealthMEDX (acquired by NetSmart), Passport Health Communications (acquired by Experian) and QTC Management (acquired by Lockheed Martin).

“We believe the evolution of connected software, data and analytics will continue to have a massive impact on the healthcare market, and we are incredibly fortunate to work with founders and CEOs who are building today’s digital health companies.”
– Steve LeSieur

For the full list of honorees, see GrowthCap’s Top 25 Healthcare Investors of 2023

Recognition presented herein are from third parties that are not affiliated with Spectrum Equity, and these third parties independently assess nominees based on based on multiple criteria. Spectrum Equity submitted the nominations to be considered for the GrowthCap Top Healthcare Growth Investors award and has paid a fee to promote/distribute this award after designation was announced. Past performance and such ranking are not a guarantee of future results. There is no guarantee that other designations or rankings would reach the same conclusions. An award may not be representative of a particular investor’s return.